David Montefiori
Overview
Explore the profile of David Montefiori including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
191
Citations
5941
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pratap P, Cottrell C, Quinn J, Carnathan D, Bader D, Tran A, et al.
bioRxiv
. 2024 Dec;
PMID: 39651156
During infection, the fusion peptide (FP) of HIV envelope glycoprotein (Env) serves a central role in viral fusion with the host cell. As such, the FP is highly conserved and...
2.
Sajadi M, Abbasi A, Tehrani Z, Siska C, Clark R, Chi W, et al.
bioRxiv
. 2024 Oct;
PMID: 39464103
Anti-HIV envelope broadly neutralizing antibodies (bnAbs) are alternatives to conventional antiretrovirals with the potential to prevent and treat infection, reduce latent reservoirs, and/or mediate a functional cure. Clinical trials with...
3.
Naicker V, Laher F, Bekker L, Seaton K, Allen M, De Rosa S, et al.
PLOS Glob Public Health
. 2024 Sep;
4(9):e0003319.
PMID: 39302924
Induction of broad, durable immune responses is a challenge in HIV vaccine development. HVTN 100 Part A administered subtype C-containing ALVAC-HIV at months 0 and 1, and ALVAC-HIV with bivalent...
4.
Agrawal P, Knudsen M, MacCamy A, Hurlburt N, Khechaduri A, Salladay K, et al.
J Virol
. 2024 Sep;
98(10):e0074424.
PMID: 39240111
Importance: HIV-1 broadly neutralizing antibodies will be a key component of an effective HIV-1 vaccine, as they prevent viral acquisition. Over the past decade, numerous broadly neutralizing antibodies (bnAbs) have...
5.
Cottrell C, Pratap P, Cirelli K, Carnathan D, Enemuo C, Antanasijevic A, et al.
NPJ Vaccines
. 2024 Jul;
9(1):126.
PMID: 38997302
Immunodominance of antibodies targeting non-neutralizing epitopes and the high level of somatic hypermutation within germinal centers (GCs) required for most HIV broadly neutralizing antibodies (bnAbs) are major impediments to the...
6.
Sui Y, Meyer T, Fennessey C, Keele B, Dadkhah K, Ma C, et al.
JCI Insight
. 2024 Jun;
9(12.
PMID: 38912579
Identifying immune correlates of protection is a major challenge in AIDS vaccine development. Anti-Envelope antibodies have been considered critical for protection against SIV/HIV (SHIV) acquisition. Here, we evaluated the efficacy...
7.
Wang S, Chan K, Wei D, Ma X, Liu S, Hu G, et al.
Nat Commun
. 2024 May;
15(1):4301.
PMID: 38773089
The vaccine elicitation of HIV tier-2-neutralization antibodies has been a challenge. Here, we report the isolation and characterization of a CD4-binding site (CD4bs) specific monoclonal antibody, HmAb64, from a human...
8.
Fazli S, Thomas A, Estrada A, Ross H, Xthona Lee D, Kazmierczak S, et al.
J Clin Invest
. 2024 Jan;
134(6).
PMID: 38227381
BACKGROUNDVaccination is typically administered without regard to site of prior vaccination, but this factor may substantially affect downstream immune responses.METHODSWe assessed serological responses to initial COVID-19 vaccination in baseline seronegative...
9.
Wang S, Chan K, Wei D, Ma X, Liu S, Hu G, et al.
Res Sq
. 2023 Oct;
PMID: 37886518
The vaccine elicitation of HIV-neutralizing antibodies with tier-2-neutralization breadth has been a challenge. Here, we report the isolation and characteristics of a CD4-binding site specific monoclonal antibody, HmAb64, from a...
10.
Evangelous T, Berry M, Venkatayogi S, LeMaster C, Geanes E, De Naeyer N, et al.
J Virol
. 2023 Oct;
97(11):e0109423.
PMID: 37874153
Despite the advent of highly active anti-retroviral therapy, people are still dying from HIV-related causes, many of whom are children, and a protective vaccine or cure is needed to end...